TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2193980

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g per day)
Number of subjects: 4524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4524
Study: 507117

Group type: EXPERIMENTAL
Intervention: Oral group (medroxyprogesterone 50 mg three times a day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intramuscular group (medroxyprogesterone 300 mg weekly)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intramuscular group
Number of subjects: 22
Study: 31361767

Group type: EXPERIMENTAL
Intervention: 150 male condoms
Number of subjects: 10245

Group type: EXPERIMENTAL
Intervention: Voluntary Counseling and Testing (VCT) only
Number of subjects: 10245

Group type: EXPERIMENTAL
Intervention: Both VCT and condoms
Number of subjects: 10245

Group type: COMPARATOR
Intervention: Control group (neither program)
Number of subjects: 10245
Study: 28644244

Group type: EXPERIMENTAL
Intervention: Robotic training with controlled force applied to pelvis and legs
Number of subjects: 23

Group type: COMPARATOR
Intervention: Treadmill only training with manual assistance as needed
Number of subjects: 23
Study: 26631327

Group type: EXPERIMENTAL
Intervention: Fractionated diet with glucose restriction (DG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study: 24668638

Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dicaine (20 mg)
Number of subjects: 70
Study: 21963266

Group type: EXPERIMENTAL
Intervention: Atropine 0.5%
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Atropine 0.1%
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (from ATOM1)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Atropine 1% (from ATOM1)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Atropine 0.1% and 0.5%
Number of subjects: 400
Study: 19436994

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (n=15)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose ketamine (n=16)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketamine users (n=18)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Polydrug controls (n=19)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nondrug-using controls (n=17)
Number of subjects: 90
Study: 17589379

Group type: EXPERIMENTAL
Intervention: 10 mg glibenclamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg glibenclamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg glibenclamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Norepinephrine requirements
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary hemodynamics
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Global oxygen transport
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gas exchange
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electrolytes
Number of subjects: 30
Study: 14693962

Group type: EXPERIMENTAL
Intervention: Intense exercise (75% HRR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moderate exercise (50% HRR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate and intense exercise
Number of subjects: 18
Study: 11476835

Group type: EXPERIMENTAL
Intervention: Environmental manipulation (active HRA)
Number of subjects: 291

Group type: COMPARATOR
Intervention: No intervention (control HRC)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Low-risk infants (LR)
Number of subjects: 291
Study: 9683310

Group type: EXPERIMENTAL
Intervention: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; beta-carotene, 6 mg) and minerals (selenium, 100 microg; zinc, 20 mg)
Number of subjects: 12735

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12735
Study: 7941961

Group type: EXPERIMENTAL
Intervention: Oral SAMe
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral desipramine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 3068098

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g as a single dose
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g on 2 consecutive days
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 29877749

Group type: EXPERIMENTAL
Intervention: Progressive strengthening
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Standard of care
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 293
Study: 29088579

Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: FX006 16 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 306
Study: 27049269

Group type: EXPERIMENTAL
Intervention: Alfentanil (5 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 µg/kg i.v. bolus) with propofol (0.5 mg/kg) and midazolam (2 mg)
Number of subjects: 99
Study: 23828877

Group type: EXPERIMENTAL
Intervention: Insole adoption
Number of subjects: 30

Group type: COMPARATOR
Intervention: No insole
Number of subjects: 30
Study: 22198652

Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty (VerSys LD/Fx; Zimmer, Warsaw, IN)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasty (VerSys Beaded FullCoat; Zimmer, Warsaw, IN)
Number of subjects: 130
Study: 20001756

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg b.i.d.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 7

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 7
Study: 18590888

Group type: EXPERIMENTAL
Intervention: Total Contact Cast (TCC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Half-shoe
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Removable Cast Walker (RCW)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 63
Study: 15531620

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 160

Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 12039468

Group type: EXPERIMENTAL
Intervention: Danazol pretreatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study: 10360848

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1 microg/kg epidural neostigmine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2 microg/kg epidural neostigmine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 4 microg/kg epidural neostigmine
Number of subjects: 48
Study: 8943972

Group type: EXPERIMENTAL
Intervention: Antroduodenal manometry in patients with gastrointestinal motility disorders
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Antroduodenal manometry in parenteral-nutrition-dependent children
Number of subjects: 95
Study: 8458317

Group type: EXPERIMENTAL
Intervention: Daily oral vitamin K1 supplement (average 88 micrograms)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 36
Study: 2429279

Group type: EXPERIMENTAL
Intervention: 2 g IV flucloxacillin 1 hour before the operation, then 1 g perorally every 8 hours for the next five days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo infusions and tablets given at the same schedule as SPG
Number of subjects: 106
Study: 31451025

Group type: EXPERIMENTAL
Intervention: Adducted arm position (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Abducted arm position (Group B)
Number of subjects: 60
Study: 31047340

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 357
Study: 27604226

Group type: EXPERIMENTAL
Intervention: Fitbit One
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Jawbone UP
Number of subjects: 29

Group type: COMPARATOR
Intervention: ActiGraph GT3X+
Number of subjects: 29
Study: 25933493

Group type: EXPERIMENTAL
Intervention: 3 g/d of α-linolenic acid (ALA) for 60 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 20
Study: 23042976

Group type: EXPERIMENTAL
Intervention: Peginterferon therapy
Number of subjects: 214
Study: 21554881

Group type: EXPERIMENTAL
Intervention: Intranasal administration of arginine vasopressin (AVP) during tasks with social evaluative threat.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal administration of arginine vasopressin (AVP) during tasks without social evaluative threat.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo during tasks without social evaluative threat.
Number of subjects: 0
Study: 17997387

Group type: EXPERIMENTAL
Intervention: Observing pointing action
Number of subjects: 0
Study: 16595209

Group type: EXPERIMENTAL
Intervention: EBMS group counseling (n = 69)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (n = 115)
Number of subjects: 227
Study: 14767408

Group type: EXPERIMENTAL
Intervention: Tropical climate (TR, 30.4 degrees C, 70% rh)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Thermoneutral climate (TN, 23.1 degrees C, 53% rh)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tropical climate (TR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Thermoneutral climate (TN)
Number of subjects: 14
Study: 11970745

Group type: EXPERIMENTAL
Intervention: Exemestane (EXE) 25 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 0
Study: 7673540

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (BT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined dermatological educational program and cognitive-behavioral treatment (DEBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dermatological educational program (DE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 0
Study: 2119558

Group type: EXPERIMENTAL
Intervention: PDPN (perdialytic parenteral nutrition)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PDPN
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no PDPN)
Number of subjects: 26
Study: 6783431

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30707847

Group type: EXPERIMENTAL
Intervention: Early Intervention (EI)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Late Intervention (LI)
Number of subjects: 46
Study: 28672318

Group type: EXPERIMENTAL
Intervention: Cooling for 72 hours at 33.5°C (n=95)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Cooling for 120 hours at 33.5°C (n=96)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Cooling for 72 hours at 32.0°C (n=90)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Cooling for 120 hours at 32.0°C (n=83)
Number of subjects: 364
Study: 25796322

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 21
Study: 23194445

Group type: EXPERIMENTAL
Intervention: Lung lavage using two aliquots of 15 mL/kg of dilute surfactant
Number of subjects: 30
Study: 21883879

Group type: EXPERIMENTAL
Intervention: Compression duplex ultrasound (CDU) screening at about 7-10 days after enrollment
Number of subjects: 5632

Group type: EXPERIMENTAL
Intervention: Compression duplex ultrasound (CDU) screening at about 25-30 days after enrollment
Number of subjects: 5632

Group type: EXPERIMENTAL
Intervention: DVT detected on the first CDU scan
Number of subjects: 5632

Group type: EXPERIMENTAL
Intervention: DVT characteristics
Number of subjects: 5632

Group type: EXPERIMENTAL
Intervention: DVT regression in patients with a DVT detected on the first CDU scan who had a second scan
Number of subjects: 5632
Study: 19261275

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with mild ovarian hyperstimulation
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) without stimulation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sequential timed natural intercourse
Number of subjects: 73
Study: 16709314

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 g/day subcutaneously)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Calcitonin (100 IU/day subcutaneously)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 104

Group type: COMPARATOR
Intervention: Calcitonin
Number of subjects: 104
Study: 15321935

Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anaesthesia (3 ml injection of lidocaine 2% and bupivacaine 0.75%)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Topical anaesthesia (four doses of proxymethocaine 0.5%)
Number of subjects: 210
Study: 11259889

Group type: EXPERIMENTAL
Intervention: Nicardipine (n = 29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroprusside (n = 31)
Number of subjects: 60
Study: 9024745

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment for 20 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7880667

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg i.v.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atracurium 0.05 mg kg‐1 i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 60
Study: 3364074

Group type: EXPERIMENTAL
Intervention: Reaferon (2 X 10(6) I. U. daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reaferon (6 X 10(6) to 9 X 10(6) I. U. daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reaferon (all doses)
Number of subjects: 0
Study: 30840643

Group type: EXPERIMENTAL
Intervention: Buying-shopping disorder (BSD) group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy control (HC) group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Dot-probe paradigm (DPP), Implicit Association Task (IAT), Go/nogo-task (GNG)
Number of subjects: 39
Study: 27919570

Group type: EXPERIMENTAL
Intervention: Exhalyzer D (EM)
Number of subjects: 182

Group type: COMPARATOR
Intervention: EasyOne Pro (NDD)
Number of subjects: 182
Study: 25783889

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Routine Care (Control)
Number of subjects: 94
Study: 24002145

Group type: EXPERIMENTAL
Intervention: Stabilized hyaluronic acid-based gel (Restylane® Vital Light) administered via micropuncture injector
Number of subjects: 30
Study: 21352939

Group type: EXPERIMENTAL
Intervention: High-dose influenza vaccine (60 μg HA per strain)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose influenza vaccine (15 μg HA per strain)
Number of subjects: 0
Study: 18166095

Group type: EXPERIMENTAL
Intervention: 4% doxycycline hyclate bioabsorbable barrier + demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Poly(DL‐lactide) PLA barrier without doxycycline + DFDBA
Number of subjects: 3

Group type: COMPARATOR
Intervention: DFDBA alone
Number of subjects: 3
Study: 17011942

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (10-20 mg daily)
Number of subjects: 7832

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 7832
Study: 12590005

Group type: EXPERIMENTAL
Intervention: Calcium plus Kava-Kava 100 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Calcium plus Kava-Kava 200 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Calcium (control)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Calcium plus Kava-Kava (both doses)
Number of subjects: 68
Study: 10813713

Group type: EXPERIMENTAL
Intervention: GM-CSF administered at a dose of 5 microg/kg/day at 10 a.m.
Number of subjects: 24

Group type: COMPARATOR
Intervention: GM-CSF administered at a dose of 5 microg/kg/day at 10 p.m.
Number of subjects: 24
Study: 8623944

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg added to 180 mg propofol
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Alfentanil 1 mg 30 s prior to propofol
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 89
Study: 1449302

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of metoprolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral dose of metoprolol (control group)
Number of subjects: 21
Study: 2866492

Group type: EXPERIMENTAL
Intervention: Terazosin 10 mg once daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29857012

Group type: EXPERIMENTAL
Intervention: Ablative fractional laser-assisted methyl aminolevulinate photodynamic therapy (AFL-MAL-PDT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional methyl aminolevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 60
Study: 26166140

Group type: EXPERIMENTAL
Intervention: Celecoxib (200mg daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Loxoprofen (180 mg daily) plus Lansoprazole (15mg daily)
Number of subjects: 150
Study: 25070302

Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (eAT)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Watchful Waiting and Supportive Care (WWSC)
Number of subjects: 464
Study: 22309271

Group type: EXPERIMENTAL
Intervention: MVC(2%LUV)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MVC(2%EPI)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MVC(3%)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MVC(3%LUV)
Number of subjects: 15
Study: 20530322

Group type: EXPERIMENTAL
Intervention: Rituximab administered at 375 mg/m² weekly for 4 doses
Number of subjects: 30
Study: 17938330

Group type: EXPERIMENTAL
Intervention: Transoral supraglottic laryngectomy by carbon dioxide laser followed by planned postoperative radiotherapy
Number of subjects: 34
Study: 15545669

Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy (CONC RT)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Sequential radiotherapy (SEQ RT)
Number of subjects: 309
Study: 11932900

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tc-MIBI SPECT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of CT and Tc-MIBI SPECT
Number of subjects: 36
Study: 9459335

Group type: EXPERIMENTAL
Intervention: 677 C-->T mutation in the MTHFR gene
Number of subjects: 337
Study: 7829706

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg two or three times a day for 14 days)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg three times daily for 20 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Tetracycline (500 mg four times a day for 14 days)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Doxycycline (14 days)
Number of subjects: 86
Study: 2650879

Group type: EXPERIMENTAL
Intervention: Naproxen 750 mg at the first symptom of the attack, total allowed 1250 mg per 24 h
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1090416

Group type: EXPERIMENTAL
Intervention: 3 mg lorazepam intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30732618

Group type: EXPERIMENTAL
Intervention: Liberal treatment protocol (3 μg/kg)
Number of subjects: 5278

Group type: COMPARATOR
Intervention: Standard treatment protocol (2 μg/kg)
Number of subjects: 5278
Study: 27565000

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795
Study: 26759667

Group type: EXPERIMENTAL
Intervention: Intervention (bed lowered and step stool readily available)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (bed raised and step stool accessible, but concealed)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intervention and Control (arm position at 90-degree angle)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Step stool utilization
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Subject characteristics (height, weight group, gender)
Number of subjects: 56
Study: 23159063

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 174
Study: 21612433

Group type: EXPERIMENTAL
Intervention: Laparoscopic retroperitoneal pyelolithotomy (LRP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 105
Study: 19376306

Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel therapy (additional loading dose followed by 150 mg daily for 6 months)
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Standard maintenance clopidogrel therapy (75 mg daily for 6 months)
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Standard clopidogrel therapy (75 mg daily for 6 months) for patients without high residual reactivity
Number of subjects: 2800
Study: 18453220

Group type: EXPERIMENTAL
Intervention: Trans-axilloareolar approach
Number of subjects: 238

Group type: COMPARATOR
Intervention: Trans-thoracoareolar approach
Number of subjects: 238
Study: 14997196

Group type: EXPERIMENTAL
Intervention: Energy and protein dense oral supplement enriched with n-3 fatty acids (EPA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control energy and protein dense oral supplement
Number of subjects: 24
Study: 11292151

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccines (subunit vaccine with MF59 - a-SUV)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Virosome subunit vaccine (v-SUV)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Whole virus vaccine (WVV)
Number of subjects: 635
Study: 9389880

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) in the form of capsules and margarine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 40